Skip to main content
RXRX
NASDAQ Life Sciences

Recursion Tops Q3 Revenue Estimates and Extends Cash Runway Into 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.83
Mkt Cap
$2.29B
52W Low
$2.77
52W High
$5.76
52W Position info
38% above low
Off High info
34% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

RXRX sits 38% above its 52-week low of $2.77.

Summary

Recursion beat Q3 revenue estimates with $18.6 million versus $14.8 million expected, narrowed its net loss to $119.0 million, and extended its cash runway into 2029. New REC-4881 data across the GI tract and a Sanofi development candidate milestone support a registrational trial planned for the second half of 2027.


Key Events · Earnings and Guidance · RXRX

  • Q3 Revenue Beats Consensus

    Total revenue came in at $18.6 million versus $14.8 million expected, up from $5.2 million a year ago, driven by a $10.0 million Sanofi milestone.

  • Cash Runway Extended Into 2029

    Cash was $561.5 million at September 30, 2026; pro forma for $187.2 million in net October offering proceeds it was about $748.7 million. Guidance is under $375 million cash operating expense for 2026 and under $360 million for 2027.

  • REC-4881 Shows Activity Across GI Tract

    87% of patients had total polyp burden reductions with a 47% median reduction; 82% had lower GI reductions and 6 of 8 patients with polyps over 5 mm saw fewer of them. A registrational trial is planned for the second half of 2027 pending FDA discussions.

  • Sanofi Options First Development Candidate

    The option triggered a $10 million milestone, bringing total Sanofi inflows to $144 million, with more than $300 million in additional milestones possible plus double-digit royalties.


Analysis · RXRX · Life Sciences

Revenue of $18.6 million beat the $14.8 million consensus, and the loss narrowed to $119.0 million from $162.3 million a year ago. Cash stood at $561.5 million at quarter-end, or roughly $748.7 million pro forma for the October offering, and management now says funding lasts into 2029 while holding 2026 cash operating expense below $375 million and guiding 2027 below $360 million. The clinical update matters as much as the numbers: REC-4881 now shows polyp reductions across both upper and lower GI tracts, including larger high-risk polyps, with a registrational trial planned for the second half of 2027 pending FDA talks. Sanofi optioning its first development candidate adds a $10 million milestone and takes total Sanofi inflows to $144 million. Fred Hassan taking the chair adds operating and commercialization experience as the company moves toward late-stage development.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RXRX was trading at $3.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $2.77 to $5.76. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RXRX - Latest Insights

RXRX
Nov 02, 2026, 4:34 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.82
Real-time Price: $2.78 info
Change: -$1.04 (-27%) info
Market Cap: $1.696B info
RXRX
Nov 02, 2026, 4:31 PM EST
Source: Reuters
Importance Score:
8
Price at Filing: $3.80
Real-time Price: $2.78 info
Change: -$1.02 (-27%) info
Market Cap: $1.696B info
RXRX
Nov 02, 2026, 4:25 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.83
Real-time Price: $2.78 info
Change: -$1.05 (-27%) info
Market Cap: $1.696B info
RXRX
Oct 16, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.17
Real-time Price: $2.78 info
Change: -$1.39 (-33%) info
Market Cap: $1.696B info
RXRX
Oct 15, 2026, 8:46 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.72
Real-time Price: $2.78 info
Change: -$0.9397 (-25%) info
Market Cap: $1.696B info